Scarica l'app Stockscreener
0.00
100.00%
-15.96
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CARA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$15.96
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$22.12M
Reddito:
$20.97M
Utile/perdita netta:
$-118.51M
Rapporto P/E:
0.00
EPS:
-2.19
Flusso di cassa netto:
$-94.45M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$29.14
Cara Therapeutics Inc Stock (CARA) Company Profile
Nome
Cara Therapeutics Inc
Settore
Industria
Telefono
203-406-3700
Indirizzo
400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
Confronta CARA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CARA
Cara Therapeutics Inc
|
0.00 | 22.12M | 20.97M | -118.51M | -94.45M | -2.19 |
|
ONC
Beigene Ltd Adr
|
236.86 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-15 | Iniziato | BTIG Research | Buy |
| 2024-06-13 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Downgrade | Needham | Buy → Hold |
| 2024-06-13 | Downgrade | Stifel | Buy → Hold |
| 2023-03-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Ripresa | Canaccord Genuity | Buy |
| 2021-08-03 | Iniziato | JP Morgan | Neutral |
| 2020-04-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-29 | Reiterato | Laidlaw | Buy |
| 2019-02-06 | Ripresa | Jefferies | Buy |
| 2019-01-15 | Iniziato | BofA/Merrill | Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Jefferies | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-12 | Ripresa | H.C. Wainwright | Buy |
| 2018-02-12 | Aggiornamento | Janney | Neutral → Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2017-06-30 | Downgrade | Janney | Buy → Neutral |
| 2017-06-30 | Reiterato | Laidlaw | Buy |
| 2017-06-30 | Reiterato | Stifel | Buy |
| 2017-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2017-03-28 | Reiterato | Laidlaw | Buy |
| 2017-03-10 | Reiterato | Laidlaw | Buy |
| 2016-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2016-08-08 | Reiterato | Needham | Buy |
Mostra tutto
Cara Therapeutics Inc Borsa (CARA) Ultime notizie
Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com - Defense World
Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars - MSN
Tvardi maps out path to Phase II data after Cara merger - The Pharma Letter
Cara Therapeutics, Inc. (NASDAQ:CARA) Receives Average Rating of “Hold” from Brokerages - Defense World
Cara Therapeutics (NASDAQ:CARA) Coverage Initiated at StockNews.com - Defense World
Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock By Investing.com - Investing.com Canada
Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
What's Going On With Cara Therapeutics Stock? - MSN
(CARA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Form 8-KCurrent report - ADVFN
TVRD stock soars to 52-week high, reaching $19.01 - Investing.com Australia
Tvardi Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Tvardi Therapeutics Closes Merger with Cara Therapeutics - citybiz
Cara Therapeutics Inc Stock Price, Quotes and Forecasts - Benzinga
Cara Therapeutics Completes Merger with Tvardi Therapeutics - TipRanks
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics - GlobeNewswire
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics - Benzinga
Cara Therapeutics announces 1-for-3 reverse stock split related to Tvardi merger - Hartford Business Journal
Cara Therapeutics (CARA) to Rebrand and Trade as Tvardi Therapeu - GuruFocus
Cara Therapeutics Announces 1-for-3 Reverse Stock Split - citybiz
Cara Therapeutics announces 1-for-3 reverse stock split By Investing.com - Investing.com South Africa
Cara Therapeutics Announces 1-For-3 Reverse Stock Split - marketscreener.com
Cara Approves Reverse Split in Connection With Tvardi Merger - marketscreener.com
Cara Therapeutics announces 1-for-3 reverse stock split - Investing.com
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Conne - GuruFocus
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics | CARA Stock News - GuruFocus
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in - GlobeNewswire
Major Transformation: Cara Therapeutics Unveils 1:3 Split Plan Before Tvardi Merger - Stock Titan
Cara Therapeutics (NASDAQ:CARA) Earns Sell Rating from Analysts at StockNews.com - Defense World
Cara Therapeutics CEO Posner sells shares worth $1,755 - MSN
Cara Therapeutics Announces Merger with Tvardi Therapeutics - TipRanks
Cara Therapeutics, Inc. (NASDAQ:CARA) Receives Average Recommendation of “Hold” from Analysts - Defense World
Cara Therapeutics approves merger and stock plans By Investing.com - Investing.com India
Cara Therapeutics approves merger and stock plans - Investing.com India
Shareholders sue to block Stamford-based Cara Therapeutics’ proposed merger with Houston biopharma firm - Hartford Business Journal
StockNews.com Begins Coverage on Cara Therapeutics (NASDAQ:CARA) - Defense World
How To Trade (CARA) - Stock Traders Daily
Cara Therapeutics announces merger with Tvardi Therapeutics By Investing.com - Investing.com South Africa
Cara Therapeutics announces merger with Tvardi Therapeutics - Investing.com
Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com - Defense World
Cannabis Stock Gainers And Losers From March 20, 2025 - Benzinga
Tvardi Therapeutics Announces Publication of Results from First-in-Human Study of TTI-101 in Patients with Advanced Solid Tumors in the Journal Clinical Cancer Research - The Manila Times
Tvardi Therapeutics Announces Publication of Results from - GlobeNewswire
Cara Therapeutics, Inc. (NASDAQ:CARA) Receives $27.84 Consensus PT from Analysts - The AM Reporter
Cara Therapeutics Inc Azioni (CARA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cara Therapeutics Inc Azioni (CARA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Feb 28 '25 |
Sale |
4.76 |
163 |
776 |
7,190 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 04 '25 |
Sale |
4.72 |
372 |
1,756 |
13,692 |
| Posner Christopher | PRESIDENT AND CEO |
Nov 04 '24 |
Sale |
0.29 |
3,668 |
1,064 |
168,768 |
| Posner Christopher | PRESIDENT AND CEO |
Aug 01 '24 |
Sale |
0.35 |
4,149 |
1,452 |
172,436 |
2.33%
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):